FDA Approves AstraZeneca's Faslodex
Faslodex® (fulvestrant) is an oestrogen receptor antagonist, indicated for the treatment of postmenopausal women with oestrogen receptor-positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy or disease progression on therapy with an anti-oestrogen.
Fulvestrant is used to treat breast cancer that has spread to other areas of the body in women who have gone through "the change of life" (menopause). It is used in patients who have not responded well to other medications (e.g., tamoxifen). Breast cancer cells need the hormone estrogen in order to grow. Fulvestrant works by blocking the effect of estrogen, slowing tumor cell growth.
Faslodex is licensed for the treatment of breast cancer in postmenopausal women. The medication works by binding to and blocking estrogen receptors. By reducing the amount of estrogen available, the medication can decrease the cancer's growth. It is only available in one dose, regardless of the severity of your cancer, age, or weight. Side effects can include nausea, weakness, and hot flashes.
Faslodex (fulvestrant) blocks the actions of estrogen in the body. Certain types of breast cancer require estrogen to grow.
Faslodex is used to treat some types of metastatic breast cancer that require estrogen to grow, in postmenopausal women whose cancer has progressed following treatment with other anti-estrogen medication. Fulvestrant is not a chemotherapy drug.
Faslodex is not a chemotherapy medicine.